Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Non-Current Deffered Revenue: 2015-2022

Historic Non-Current Deffered Revenue for Arrowhead Pharmaceuticals (ARWR) over the last 7 years, with Sep 2022 value amounting to $56.0 million.

  • Arrowhead Pharmaceuticals' Non-Current Deffered Revenue fell 98.80% to $1.1 million in Q1 2023 from the same period last year, while for Mar 2023 it was $1.1 million, marking a year-over-year decrease of 98.80%. This contributed to the annual value of $56.0 million for FY2022, which is 57.45% down from last year.
  • According to the latest figures from FY2022, Arrowhead Pharmaceuticals' Non-Current Deffered Revenue is $56.0 million, which was down 57.45% from $131.5 million recorded in FY2021.
  • In the past 5 years, Arrowhead Pharmaceuticals' Non-Current Deffered Revenue ranged from a high of $131.5 million in FY2021 and a low of $1.7 million during FY2018.
  • For the 2-year period, Arrowhead Pharmaceuticals' Non-Current Deffered Revenue averaged around $93.7 million, with its median value being $93.7 million (2021).
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Non-Current Deffered Revenue spiked by 195.70% in 2019, and later crashed by 57.45% in 2022.
  • Over the past 4 years, Arrowhead Pharmaceuticals' Non-Current Deffered Revenue (Yearly) stood at $1.7 million in 2018, then skyrocketed by 195.70% to $5.0 million in 2019, then reached $131.5 million in 2021, then crashed by 57.45% to $56.0 million in 2022.